March 24, 2015
PDX Pharmaceutical, in collaboration with the Biomedical Engineering Department of Oregon Health and Science University, co-authored a paper published in the Advanced Functional Materials Journal that describes the novel nanoparticle siRNA delivery platform and its utility for targeting HER2-positive breast cancer. Approximately 15-25% of diagnosed breast cancers are classified as HER2-positive. HER2-positive breast cancers tend to be more aggressive, have poor prognosis and often become refractory to standard care.
The published study establishes a new and effective strategy to inhibit HER2-positive tumor growth by suppressing HER2 expression with siRNA, made possible by the newly developed nanoparticle delivery platform. Of particular note, data shows that cancers that are resistant to current HER2 targeted therapies respond well to the siRNA mediated HER2 silencing. The published research represents an important new development in an area that currently has few treatment options.
To read the paper click here.